See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report for: ARGS
Argos Therapeutics is a biopharmaceutical company that focuses on the development of immunotherapies to treat cancer and infectious diseases. Argos is a Zacks Rank #2 (Buy), and it has clinical stage programs in phase 3 (metastatic renal cell carcinoma), phase 2b (HIV), and phase 1a (systemic lupus erythematosus). The company sees more share price fluctuation than your average stock, as it has a beta of 2.21.
Argos’ earnings are projected to grow by 42.25%. Its sales are also expected to increase by 227.95% this year. Our quarterly consensus estimate has increased significantly over the last 30 days. A month ago, our EPS consensus for this quarter estimated earnings of -$0.72 per share. Since then, the consensus has climbed and it now estimates EPS of -$0.56. In the last 30 days, our fiscal year EPS consensus has gone from -$2.87 to -$2.12. Argos is expected to release its earnings in mid-May.
Source – Zacks
DURHAM, N.C., May 05, 2016 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on theArcelis® technology platform, today announced that the Company’s first quarter 2016 financial results will be released after the market close on Thursday, May 12, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
Source – Company Press Release
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Hot small cap stocks
small cap stock picks
FDA approval stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news